These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 24403854)

  • 1. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
    Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
    Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
    Xiao Y; Elkins K; Durieux JK; Lee L; Oeh J; Yang LX; Liang X; DelNagro C; Tremayne J; Kwong M; Liederer BM; Jackson PK; Belmont LD; Sampath D; O'Brien T
    Neoplasia; 2013 Oct; 15(10):1151-60. PubMed ID: 24204194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
    Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
    Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples.
    Duarte-Pereira S; Silva SS; Azevedo L; Castro L; Amorim A; Silva RM
    Sci Rep; 2014 Sep; 4():6311. PubMed ID: 25201160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.
    Cerna D; Li H; Flaherty S; Takebe N; Coleman CN; Yoo SS
    J Biol Chem; 2012 Jun; 287(26):22408-17. PubMed ID: 22570471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
    Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
    Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
    Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
    Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
    Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.
    Zhu X; Li Y; Liu H; Wang Y; Sun R; Jiang Z; Hou C; Hou X; Huang S; Zhang H; Wang H; Jiang B; Yang X; Xu B; Fan G
    Cell Chem Biol; 2024 Jun; 31(6):1203-1218.e17. PubMed ID: 38906111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
    Olesen UH; Hastrup N; Sehested M
    APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
    Zhao G; Green CF; Hui YH; Prieto L; Shepard R; Dong S; Wang T; Tan B; Gong X; Kays L; Johnson RL; Wu W; Bhattachar S; Del Prado M; Gillig JR; Fernandez MC; Roth KD; Buchanan S; Kuo MS; Geeganage S; Burkholder TP
    Mol Cancer Ther; 2017 Dec; 16(12):2677-2688. PubMed ID: 29054982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
    Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the NAD
    Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
    Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.